2026 Q3 Portfolio Activity
In 2026 Q3, BAKER BROS. ADVISORS LP maintained a portfolio of 88 distinct positions. The most significant new addition was First Tracks Biotherapeutics, , now representing 0.08% of the total fund value. They heavily accumulated shares in Kodiak Sciences Inc., increasing the position by 9.7%. The fund also reduced its exposure to Celcuity Inc. by 39.2%.
Position History
hover any row below to update
Loading…
Total Positions
88
Quarter
2026 Q3
Top Holding
INCY (17.7%)
Top 10 Concentration
77.2%
Turnover Rate
23.4%
Sector HHI
0.18
Items per page:
Showing 1-50 of 88
BAKER BROS. ADVISORS LP Full Holdings List — 2026 Q3
| Stock | History | Sector / Type | Port % | Prev % | Rank / Prev | Conviction | Change | % Change | Influence | Shares | Mkt Value | Avg Cost | Price Held | 1st Owned | Source | Source Date | Date Reported | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
INCY
Incyte Corporat...
|
Healthcare | 17.74% | 17.48% |
#1
Prev: #1
|
6.5 |
—
|
322 | 0.0% |
P
S
|
30,762,652 | $3,733,047,820 |
$56.34
+112.4%
|
2003 Q2 | 13F Filing | 2026-09-30 | 2026-11-16 | ||
|
ONC
BeOne Medicines...
|
Healthcare | 15.36% | 12.57% |
#2
Prev: #2
|
6.0 |
—
|
30,768 | 0.3% |
P
S
|
8,832,335 | $3,232,104,670 |
$136.84
+202.0%
|
2016 Q1 | 13F Filing | 2026-09-30 | 2026-11-16 | ||
|
RVMD
Revolution Medi...
|
Healthcare | 10.38% | 10.74% |
#3
Prev: #3
|
5.5 |
—
|
-806,039 | -7.0% |
P
S
|
10,637,318 | $2,183,415,893 |
$56.67
+182.0%
|
2021 Q1 | 13F Filing | 2026-09-30 | 2026-11-16 | ||
|
KOD
Kodiak Sciences...
|
Healthcare | 9.85% | 3.89% |
#4
5
Prev: #9
|
6.4 |
—
|
1,941,755 | 9.7% |
P
S
|
21,860,941 | $2,072,417,207 | 2018 Q4 | 13F Filing | 2026-09-30 | 2026-11-16 | |||
|
MDGL
Madrigal Pharma...
|
Healthcare | 5.13% | 5.77% |
#5
1
Prev: #4
|
3.6 |
—
|
no change | no change |
P
S
|
2,143,131 | $1,080,052,299 | 2016 Q3 | 13F Filing | 2026-09-30 | 2026-11-16 | |||
|
INSM
Insmed Incorpor...
|
Healthcare | 4.77% | 4.70% |
#6
1
Prev: #7
|
2.9 |
—
|
no change | no change |
P
S
|
8,796,111 | $1,003,988,110 | 2012 Q4 | 13F Filing | 2026-09-30 | 2026-11-16 | |||
|
KYMR
Kymera Therapeu...
|
Healthcare | 4.60% | 4.97% |
#7
1
Prev: #6
|
2.8 |
—
|
no change | no change |
P
S
|
8,657,242 | $967,793,083 | 2020 Q3 | 13F Filing | 2026-09-30 | 2026-11-16 | |||
|
ACAD
ACADIA Pharmace...
|
Healthcare | 4.11% | 5.44% |
#8
3
Prev: #5
|
2.6 |
—
|
no change | no change |
P
S
|
42,912,904 | $864,695,016 | 2005 Q1 | 13F Filing | 2026-09-30 | 2026-11-16 | |||
|
GRAL
GRAIL, Inc.
|
Healthcare | 2.68% | 1.38% |
#9
5
Prev: #14
|
2.1 |
—
|
no change | no change |
P
S
|
4,028,614 | $564,489,394 | 2024 Q4 | 13F Filing | 2026-09-30 | 2026-11-16 | |||
|
SMMT
Summit Therapeu...
|
Healthcare | 2.63% | 2.39% |
#10
3
Prev: #13
|
2.1 |
—
|
no change | no change |
P
S
|
32,786,348 | $554,417,145 | 2022 Q4 | 13F Filing | 2026-09-30 | 2026-11-16 | |||
|
RYTM
Rhythm Pharmace...
|
Healthcare | 2.54% | 3.12% |
#11
1
Prev: #10
|
2.0 |
—
|
no change | no change |
P
S
|
5,604,483 | $533,630,849 | 2017 Q4 | 13F Filing | 2026-09-30 | 2026-11-16 | |||
|
PRAX
Praxis Precisio...
|
Healthcare | 2.43% | 2.94% |
#12
1
Prev: #11
|
2.0 |
—
|
no change | no change |
P
S
|
1,753,198 | $510,583,854 | 2024 Q1 | 13F Filing | 2026-09-30 | 2026-11-16 | |||
|
ABCL
AbCellera Biolo...
|
Healthcare | 2.29% | 1.30% |
#13
2
Prev: #15
|
1.4 |
—
|
1 | 0.0% |
P
S
|
33,012,139 | $481,647,108 | 2020 Q4 | 13F Filing | 2026-09-30 | 2026-11-16 | |||
|
ALKS
Alkermes plc
|
Healthcare | 1.93% | 2.63% |
#14
2
Prev: #12
|
1.8 |
—
|
no change | no change |
P
S
|
10,012,267 | $405,697,059 | 2003 Q3 | 13F Filing | 2026-09-30 | 2026-11-16 | |||
|
CELC
Celcuity Inc.
|
Healthcare | 1.82% | 4.15% |
#15
7
Prev: #8
|
0.7 |
—
|
-3,100,000 | -39.2% |
P
S
|
4,815,792 | $382,951,780 | 2023 Q3 | 13F Filing | 2026-09-30 | 2026-11-16 | |||
|
KNSA
Kiniksa Pharmac...
|
Healthcare | 1.00% | 0.91% |
#16
2
Prev: #18
|
1.4 |
—
|
no change | no change |
P
S
|
2,834,643 | $211,492,714 | 2024 Q2 | 13F Filing | 2026-09-30 | 2026-11-16 | |||
|
IDYA
IDEAYA Bioscien...
|
Healthcare | 0.91% | 0.94% |
#17
Prev: #17
|
1.4 |
—
|
no change | no change |
P
S
|
5,010,030 | $192,485,353 | 2019 Q2 | 13F Filing | 2026-09-30 | 2026-11-16 | |||
|
EWTX
Edgewise Therap...
|
Healthcare | 0.71% | 0.75% |
#18
4
Prev: #22
|
1.3 |
—
|
no change | no change |
P
S
|
3,701,719 | $150,289,791 | 2021 Q1 | 13F Filing | 2026-09-30 | 2026-11-16 | |||
|
REPL
Replimune Group...
|
Healthcare | 0.69% | 0.61% |
#19
4
Prev: #23
|
1.3 |
—
|
no change | no change |
P
S
|
11,045,336 | $146,240,249 | 2020 Q2 | 13F Filing | 2026-09-30 | 2026-11-16 | |||
|
ROIV
Roivant Science...
|
Healthcare | 0.64% | 0.84% |
#20
1
Prev: #19
|
0.3 |
—
|
-1,056,479 | -22.4% |
P
S
|
3,660,352 | $133,859,073 | 2022 Q4 | 13F Filing | 2026-09-30 | 2026-11-16 | |||
|
ARWR
Arrowhead Pharm...
|
Healthcare | 0.53% | 0.81% |
#21
1
Prev: #20
|
0.7 |
—
|
-283,730 | -14.2% |
P
S
|
1,709,053 | $111,857,519 | 2013 Q3 | 13F Filing | 2026-09-30 | 2026-11-16 | |||
|
NRIX
Nurix Therapeut...
|
Healthcare | 0.52% | 0.57% |
#22
2
Prev: #24
|
1.2 |
—
|
no change | no change |
P
S
|
4,658,556 | $110,454,363 | 2020 Q3 | 13F Filing | 2026-09-30 | 2026-11-16 | |||
|
IMVT
Immunovant, Inc...
|
Healthcare | 0.44% | 1.05% |
#23
7
Prev: #16
|
0.2 |
—
|
-2,664,843 | -49.0% |
P
S
|
2,770,377 | $93,583,335 | 2023 Q3 | 13F Filing | 2026-09-30 | 2026-11-16 | |||
|
CLDX
Celldex Therape...
|
Healthcare | 0.40% | 0.22% |
#24
16
Prev: #40
|
3.2 |
—
|
1,382,373 | 116.9% |
P
S
|
2,564,984 | $83,131,131 | 2023 Q4 | 13F Filing | 2026-09-30 | 2026-11-16 | |||
|
DNLI
Denali Therapeu...
|
Healthcare | 0.37% | 0.48% |
#25
3
Prev: #28
|
1.1 |
—
|
no change | no change |
P
S
|
3,734,336 | $77,188,725 | 2020 Q1 | 13F Filing | 2026-09-30 | 2026-11-16 | |||
|
DNTH
Dianthus Therap...
|
Healthcare | 0.36% | 0.42% |
#26
4
Prev: #30
|
1.1 |
—
|
no change | no change |
P
S
|
852,164 | $75,033,040 | 2025 Q2 | 13F Filing | 2026-09-30 | 2026-11-16 | |||
|
N/A
Celcuity Inc.
|
|
Bond/Debt | 0.26% | 0.35% |
#27
5
Prev: #32
|
1.1 |
—
|
no change | no change |
P
S
|
30,750,000 | $55,457,225 | — | 13F Filing | 2026-09-30 | 2026-11-16 | ||
|
RAPP
Rapport Therape...
|
Healthcare | 0.25% | 0.32% |
#28
5
Prev: #33
|
1.1 |
—
|
no change | no change |
P
S
|
1,547,090 | $51,982,224 | 2025 Q2 | 13F Filing | 2026-09-30 | 2026-11-16 | |||
|
GLUE
Monte Rosa Ther...
|
Healthcare | 0.25% | 0.53% |
#29
3
Prev: #26
|
1.1 |
—
|
no change | no change |
P
S
|
4,345,736 | $51,844,630 | 2023 Q1 | 13F Filing | 2026-09-30 | 2026-11-16 | |||
|
RLAY
Relay Therapeut...
|
Healthcare | 0.24% | 0.27% |
#30
6
Prev: #36
|
1.1 |
—
|
no change | no change |
P
S
|
2,826,783 | $51,023,433 | 2023 Q1 | 13F Filing | 2026-09-30 | 2026-11-16 | |||
|
IONS
Ionis Pharmaceu...
|
Healthcare | 0.22% | 0.81% |
#31
10
Prev: #21
|
0.1 |
—
|
-1,023,863 | -50.0% |
P
S
|
1,023,864 | $45,715,528 | 2006 Q2 | 13F Filing | 2026-09-30 | 2026-11-16 | |||
|
GPCR
Structure Thera...
|
Healthcare | 0.21% | 0.39% |
#32
1
Prev: #31
|
1.1 |
—
|
no change | no change |
P
S
|
1,432,529 | $44,795,182 | 2024 Q3 | 13F Filing | 2026-09-30 | 2026-11-16 | |||
|
ELVN
Enliven Therape...
|
Healthcare | 0.20% | 0.23% |
#33
6
Prev: #39
|
1.1 |
—
|
no change | no change |
P
S
|
905,191 | $41,493,955 | 2024 Q1 | 13F Filing | 2026-09-30 | 2026-11-16 | |||
|
BCYC
Bicycle Therape...
|
Healthcare | 0.19% | 0.23% |
#34
4
Prev: #38
|
1.1 |
—
|
no change | no change |
P
S
|
10,885,357 | $40,058,114 | 2022 Q3 | 13F Filing | 2026-09-30 | 2026-11-16 | |||
|
PRLD
Prelude Therape...
|
Healthcare | 0.19% | 0.27% |
#35
Prev: #35
|
1.1 |
—
|
no change | no change |
P
S
|
10,123,824 | $39,584,152 | 2020 Q3 | 13F Filing | 2026-09-30 | 2026-11-16 | |||
|
MIRM
Mirum Pharmaceu...
|
Healthcare | 0.18% | 0.26% |
#36
1
Prev: #37
|
1.1 |
—
|
no change | no change |
P
S
|
445,975 | $38,121,943 | 2019 Q3 | 13F Filing | 2026-09-30 | 2026-11-16 | |||
|
DSGN
Design Therapeu...
|
Healthcare | 0.18% | 0.19% |
#37
5
Prev: #42
|
2.1 |
—
|
309,714 | 11.6% |
P
S
|
2,988,144 | $37,560,970 | 2021 Q1 | 13F Filing | 2026-09-30 | 2026-11-16 | |||
|
IMTX
Immatics N.V.
|
Healthcare | 0.18% | 0.48% |
#38
11
Prev: #27
|
0.1 |
—
|
-5,251,883 | -55.2% |
P
S
|
4,256,682 | $37,373,668 | 2020 Q3 | 13F Filing | 2026-09-30 | 2026-11-16 | |||
|
STOK
Stoke Therapeut...
|
Healthcare | 0.16% | 0.55% |
#39
14
Prev: #25
|
0.1 |
—
|
-2,022,698 | -60.6% |
P
S
|
1,313,999 | $34,163,974 | 2022 Q3 | 13F Filing | 2026-09-30 | 2026-11-16 | |||
|
TRDA
Entrada Therape...
|
Healthcare | 0.15% | 0.19% |
#40
3
Prev: #43
|
1.1 |
—
|
no change | no change |
P
S
|
5,072,730 | $32,211,836 | 2021 Q4 | 13F Filing | 2026-09-30 | 2026-11-16 | |||
|
NGNE
Neurogene Inc.
|
Healthcare | 0.13% | 0.16% |
#41
5
Prev: #46
|
1.1 |
—
|
no change | no change |
P
S
|
991,691 | $27,588,844 | 2023 Q4 | 13F Filing | 2026-09-30 | 2026-11-16 | |||
|
XNCR
Xencor, Inc.
|
Healthcare | 0.13% | 0.09% |
#42
18
Prev: #60
|
1.1 |
—
|
no change | no change |
P
S
|
1,102,106 | $27,497,545 | 2013 Q4 | 13F Filing | 2026-09-30 | 2026-11-16 | |||
|
SNSE
Faeth Therapeut...
|
Healthcare | 0.11% | 0.16% |
#43
1
Prev: #44
|
0.0 |
—
|
-482,986 | -37.5% |
P
S
|
803,425 | $23,893,860 | 2026 Q2 | 13F Filing | 2026-09-30 | 2026-11-16 | |||
|
ABSI
Absci Corporati...
|
Healthcare | 0.11% | 0.12% |
#44
7
Prev: #51
|
1.0 |
—
|
no change | no change |
P
S
|
2,134,803 | $22,991,828 | 2025 Q4 | 13F Filing | 2026-09-30 | 2026-11-16 | |||
|
IRON
Disc Medicine, ...
|
Healthcare | 0.11% | 0.13% |
#45
5
Prev: #50
|
1.0 |
—
|
no change | no change |
P
S
|
349,657 | $22,888,547 | 2024 Q4 | 13F Filing | 2026-09-30 | 2026-11-16 | |||
|
RCUS
Arcus Bioscienc...
|
Healthcare | 0.10% | 0.13% |
#46
3
Prev: #49
|
1.0 |
—
|
no change | no change |
P
S
|
844,816 | $21,821,597 | 2018 Q2 | 13F Filing | 2026-09-30 | 2026-11-16 | |||
|
GENB
Generate Biomed...
|
Healthcare | 0.10% | 0.12% |
#47
5
Prev: #52
|
1.0 |
—
|
no change | no change |
P
S
|
1,423,602 | $21,382,502 | 2026 Q1 | 13F Filing | 2026-09-30 | 2026-11-16 | |||
|
TSHA
Taysha Gene The...
|
Healthcare | 0.09% | 0.14% |
#48
Prev: #48
|
1.0 |
—
|
no change | no change |
P
S
|
4,004,756 | $19,503,162 | 2023 Q3 | 13F Filing | 2026-09-30 | 2026-11-16 | |||
|
AKTS
Aktis Oncology,...
|
Healthcare | 0.09% | 0.16% |
#49
4
Prev: #45
|
1.0 |
—
|
no change | no change |
P
S
|
996,351 | $19,398,954 | 2026 Q1 | 13F Filing | 2026-09-30 | 2026-11-16 | |||
|
JBIO
Jade Bioscience...
|
Healthcare | 0.08% | 0.14% |
#50
3
Prev: #47
|
1.0 |
—
|
no change | no change |
P
S
|
1,230,426 | $17,287,485 | 2025 Q4 | 13F Filing | 2026-09-30 | 2026-11-16 |
Showing 1-50 of 88 holdings